TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Increased intensity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ventilator-associated pneumonia (VAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in clinical pulmonary infection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower white blood cell count at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum sCTLA‐4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary and secondary outcomes post-mTBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: home exercise outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: task-unrelated images or thoughts
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BMI Z-score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute renal failure (ARF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of acute renal failure (ARF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: interdose morning plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: weight gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of acute lower respiratory infection
Endpoint domain: Adverse events/effects
Primary endpoint: Conditioned pain modulation effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NMR stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated Partial Thromboplastin Time (APTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grades 3-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Lequesne's index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSAIDs and analgesics intake reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major response (vomiting control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (no vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first episode of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trabecular number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trabecular separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental cost per life-year gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Living donor kidney transplantation discussion and pursuit behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite ischemia at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: percentage reduction in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of neutrophils in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of myeloperoxidase (MPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of LTB4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hypothermia on admission to NICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-6 h weighted mean FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain scores at the time of needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of cry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood coagulability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6 Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux correction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-hour recovery value for packed RBC units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of hemolysis on Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean corrected count increment of platelet components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Projected relative risk for breast cancer based on fat intake percentiles
Endpoint domain: Mortality/survival
Primary endpoint: Response to music in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pleasure ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratings of wanting to listen to music
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Variceal recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding related to recurrent varices
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality predictor (Child Pugh score ≥8)
Endpoint domain: Mortality/survival
Primary endpoint: drinks/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % days abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: musculoskeletal comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: visual comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in NRS for NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CHEPs amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antihyperalgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic and diastolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of target blood pressure (diastolic BP seated < 90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lean mass accrual
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivation to exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Crossover to surgical repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency operations required
Endpoint domain: Adverse events/effects
Primary endpoint: Enrollment of family and friends in smoking cessation program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean PEFR (Peak Expiratory Flow Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of days with total HSV-2 shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NT-proBNP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IT-T concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: JTC reasoning bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascending of the testis after orchiopexy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Risk of damage to testicular tissue
Endpoint domain: Adverse events/effects
Primary endpoint: Responder rates (>/=30% improvement from baseline PANSS total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of POSEH
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in daily living
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in work skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 10-year relapse-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Fullness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of hip fractures
Endpoint domain: Mortality/survival
Primary endpoint: Total number of nonvertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: maximal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hard-tissue debris accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD loss after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of mild irritation at the infusion site
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events associated with the drug
Endpoint domain: Adverse events/effects
Primary endpoint: Trough plasma phenytoin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average CT value of the internal iliac artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: efficacy of unloading shoes in knee OA management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lean mass changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscular fitness improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean lymphocyte nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean heart rate nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage change in lumbar spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage change in femoral neck bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DMQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plate removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neurological events
Endpoint domain: Adverse events/effects
Primary endpoint: Implementation of preventive programmes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Negative conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rates of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean score comparison between JVIR and CVIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic opacification duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hct and Hb values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Suction drain blood volume output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MAS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCAT score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lipoprotein profile improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite endpoints
Endpoint domain: Mortality/survival
Primary endpoint: Mean cost per patient to the hospital of treating adverse reactions to contrast material
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in BSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Experience of physical IPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to type 2 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Decrease in chylomicron lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Decrease in chylomicron postprandial apoB‐48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Number of relapsed patients
Endpoint domain: Mortality/survival
Primary endpoint: Number of recurrences per patient
Endpoint domain: Mortality/survival
Primary endpoint: Time to depressive, manic, hypomanic, and mixed recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervals between donations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the plasma 7‐hydroxycoumarin versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of 7‐hydroxycoumarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 7‐hydroxycoumarin excretion over a 24‐hour period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily metabolic rate (ADMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean HE area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients free of AF recurrence at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: clinical success (reduction in contracture to ≤5° of full extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence at 12 months (increase in joint contracture to ≥20°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of anterior knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive response rates on the Clinical Global Impression ‐ Improvement scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean difference on Brief Autism Mealtime Behaviors Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted standard mean difference for grams consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of paradoxical reaction
Endpoint domain: Adverse events/effects
Primary endpoint: chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived entrance-related barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived outdoor barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dryness of mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waking up due to wetness on the face
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Eicosapentaenoic acid (EPA) levels in mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol (T-CHO) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low density lipoprotein cholesterol (LDL-C) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Arterial Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum mean testicular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pubertal duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year tumour-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Cross-sectional area of the femoral vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS/WOMAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant weight gain (≥7% increase)
Endpoint domain: Adverse events/effects
Primary endpoint: New-onset metabolic syndrome (MBS)
Endpoint domain: Adverse events/effects
Primary endpoint: YMRS 50% responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC-function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking time on a spongy surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Requirement of additional antihypertensive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIRS development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Urosepsis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mortality due to septic shock
Endpoint domain: Mortality/survival
Primary endpoint: stress perfusion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in ischemic segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulse rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: retinal artery diameter decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Discomfort with separator placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of IFN‐γ ELISpot responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of Gag and/or Env IFN‐γ ELISpot responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ and CD8+ T cell responses measured as IFN‐γ/IL‐2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intraocular RMS aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased alanine aminotransferase (ALT) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Increased alkaline phosphatase (ALP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in self-perceived HIV risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of complete abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of drop-outs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: eosinophilic infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: visual attention deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PCO measured by EPCO 2000
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSCA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients cardioverted at the first attempt with 50 J
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shock induced discomfort (pain score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for sedatives/anesthetics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinical and bacteriologic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse reaction frequency
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year implant success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: amount and quality of new bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived caregiver burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: nonfatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in S. aureus nasal carriage
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of planned chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disability Rating Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes